Voyager Therapeutics Taps Nathan Jorgensen of Vor Bio as CFO, Effective July 8
Portfolio Pulse from Benzinga Newsdesk
Voyager Therapeutics, Inc. (NASDAQ:VYGR) has appointed Nathan Jorgensen, Ph.D., MBA, as Chief Financial Officer (CFO), effective July 8, 2024. Jorgensen brings extensive experience in investment banking, healthcare investing, sell-side research, and operational roles in biotech, with a focus on neuroscience. He was previously CFO at Vor Biopharma Inc.
June 13, 2024 | 11:20 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Voyager Therapeutics has appointed Nathan Jorgensen as CFO, effective July 8, 2024. Jorgensen's extensive experience in biotech and finance is expected to strengthen Voyager's financial strategy and operations.
The appointment of a new CFO with extensive experience in biotech and finance is likely to positively impact Voyager Therapeutics' financial strategy and operations, potentially boosting investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100